Publications by authors named "Josep M Del Campo"
Purpose: We present the results of a post hoc tumor tissue analysis from the phase 3 MILO/ENGOT-ov11 study (NCT01849874).
Patients And Methods: Mutation/copy-number analysis was performed on tissue obtained pre-randomization. The Kaplan-Meier method was used to estimate progression-free survival (PFS).
Purpose: Low-grade serous ovarian carcinomas (LGSOCs) have historically low chemotherapy responses. Alterations affecting the MAPK pathway, most commonly KRAS/BRAF, are present in 30%-60% of LGSOCs. The purpose of this study was to evaluate binimetinib, a potent MEK1/2 inhibitor with demonstrated activity across multiple cancers, in LGSOC.
View Article and Find Full Text PDFImportance: Locoregionally advanced head and neck squamous cell cancer (HNSCC) is treated curatively; however, risk of recurrence remains high among some patients. The ERBB family blocker afatinib has shown efficacy in recurrent or metastatic HNSCC.
Objective: To assess whether afatinib therapy after definitive chemoradiotherapy (CRT) improves disease-free survival (DFS) in patients with HNSCC.
Purpose: In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor, prolonged progression-free survival in patients with platinum-sensitive, recurrent ovarian cancer who had a response to their last platinum-based chemotherapy. The objective of the study was to assess the clinical benefit and patient-reported outcomes in patients who had a partial response (PR) and complete response (CR) to their last platinum-based therapy.
View Article and Find Full Text PDFBackground: Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2, improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial.
Methods: TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres) in 14 countries.
Background: Quality of life (QOL) has become an important complementary endpoint in cancer clinical studies alongside more traditional assessments (eg, tumour response, progression-free survival, overall survival). Niraparib maintenance treatment has been shown to significantly improve progression-free survival in patients with recurrent ovarian cancer. We aimed to assess whether the benefits of extending progression-free survival are offset by treatment-associated toxic effects that affect QOL.
View Article and Find Full Text PDFArticle Synopsis
- No cure exists for recurrent and metastatic cervical cancer, and current chemotherapy options are limited and often ineffective.
- Immune checkpoint inhibitors like pembrolizumab have demonstrated strong responses in some cancer patients, but their effectiveness varies among individuals.
- A case study is presented where a patient with advanced cervical cancer, who had tried all other treatments, responded remarkably well to pembrolizumab, highlighting its potential in tough cases.
Purpose Seribantumab is a fully human immunoglobulin G2 monoclonal antibody that binds to human epidermal growth factor receptor (HER) 3 (ErbB3), blocking heregulin (HRG) -mediated ErbB3 signaling and inducing ErbB3 receptor downregulation. This open-label randomized phase II study evaluated progression-free survival (PFS) with seribantumab in combination with once-per-week paclitaxel compared with paclitaxel alone in patients with platinum-resistant or -refractory ovarian cancer. A key secondary objective was to determine if any of five prespecified biomarkers predicted benefit from seribantumab.
View Article and Find Full Text PDFPurpose: The AGO-OVAR 2.29/ENGOT-ov14/PENELOPE prospectively randomized phase III trial evaluated the addition of pertuzumab to chemotherapy in patients with platinum-resistant ovarian carcinoma with low tumor human epidermal growth factor receptor 3 (HER3) mRNA expression. We report the results of the primary efficacy analysis.
View Article and Find Full Text PDFArticle Synopsis
- In platinum-resistant ovarian cancer, the addition of pertuzumab to gemcitabine showed improved progression-free survival in patients with low HER3 messenger RNA expression, prompting further investigation through the PENELOPE trial.
- Part 1 of the study involved 50 patients receiving either topotecan or paclitaxel combined with pertuzumab, aiming to assess safety and tolerability.
- Results indicated that disease progression was the main reason for treatment discontinuation, with common side effects being anemia and fatigue, and overall median progression-free survival was around 4.1 to 4.2 months for the different treatment combinations.
Objective: PF-04691502 and gedatolisib (PF-05212384) are potent, dual PI3K/mTOR inhibitors. This phase II study (B1271004) was conducted in patients with recurrent endometrial cancer following platinum-containing chemotherapy. The primary endpoint was to assess clinical benefit response (complete or partial response, or stable disease for ≥16weeks) following treatment with PF-04691502 or gedatolisib.
View Article and Find Full Text PDFVolasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
J Clin Oncol
March 2016
Purpose: Volasertib is a potent and selective cell-cycle kinase inhibitor that induces mitotic arrest and apoptosis by targeting Polo-like kinase. This phase II trial evaluated volasertib or single-agent chemotherapy in patients with platinum-resistant or -refractory ovarian cancer who experienced failure after treatment with two or three therapy lines.
Patients And Methods: Patients were randomly assigned to receive either volasertib 300 mg by intravenous infusion every 3 weeks or an investigator's choice of single-agent, nonplatinum, cytotoxic chemotherapy.
Objective: AGO-OVAR 16 demonstrated that pazopanib maintenance therapy significantly increased progression-free survival (PFS) in patients with ovarian cancer whose disease had not progressed after first-line therapy. In a sub-study, we evaluated the effect of clinically important germline BRCA1 and BRCA2 mutations on PFS.
Methods: Of 940 AGO-OVAR 16 participants, 664 had BRCA1/2 exon sequencing data (pazopanib, n=335; placebo, n=329).
Background: Analysis of progression-free survival (PFS) as the primary endpoint in advanced epithelial ovarian, fallopian tube, and primary peritoneal cancer (AEOC) trials may be confounded by the difficulty of radiologic evaluation of disease progression and the potential for discrepancy between investigator and blinded independent central assessments. PFS as assessed by local investigator (INV) was the primary endpoint of AGO-OVAR16, a randomized, double-blind trial of pazopanib maintenance therapy in AEOC. To confirm the robustness of the primary analysis, PFS was also evaluated by blinded independent central review (BICR).
View Article and Find Full Text PDFPurpose: Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit. Preclinical and clinical studies support VEGFR and PDGFR as targets for advanced ovarian cancer treatment. This study evaluated the role of pazopanib maintenance therapy in patients with ovarian cancer whose disease did not progress during first-line chemotherapy.
View Article and Find Full Text PDFOvarian cancer (OC) is the most lethal gynecological malignancy among women. Over 70% of women with OC are diagnosed in advanced stages and most of these cases are incurable. Although most patients respond well to primary chemotherapy, tumors become resistant to treatment.
View Article and Find Full Text PDFArticle Synopsis
- Researchers analyzed gene expression in 1,707 cancer samples across six types: breast, ovarian, brain, colorectal, lung adenocarcinoma, and squamous cell lung cancer.
- They discovered that Basal-like breast tumors are distinct from other breast cancers, sharing more similarities with squamous cell lung cancers.
- The findings indicate that clinical trials should target tumors with similar molecular profiles, especially focusing on Basal-like breast cancer and squamous cell lung carcinoma, rather than solely considering their tissue of origin.
Article Synopsis
- This study tested the effectiveness and safety of intravenous aflibercept in patients with hard-to-treat ovarian cancer who had progressed after other treatments.
- The participants were given either a 2 mg/kg or 4 mg/kg dose every two weeks, with the main goal of measuring the overall response rate (ORR) to the treatment.
- The results showed low response rates, with only 0.9% in the 2 mg/kg group and 4.6% in the 4 mg/kg group, while significant side effects like hypertension and fatigue were noted.
Article Synopsis
- The study used dynamic contrast-enhanced MRI to evaluate how a tyrosine kinase inhibitor, lapatinib, affects blood flow in tumors.
- Nine subjects were analyzed before and after treatment, revealing a decrease in a specific kinetic parameter (K(trans)) in the lapatinib group, although results were not statistically significant.
- The Bayesian hierarchical model (BHM) effectively accounted for variability in the data, demonstrating that it could be a useful method for analyzing imaging data in clinical studies, despite the small sample size and lack of significant findings.
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer.
Expert Rev Anticancer Ther
June 2010
In the absence of a curative treatment for patients with recurrent ovarian cancer, many agents have shown different levels of activity in the control of this disease. Trabectedin is an antineoplastic agent originally derived from the Caribbean marine tunicate Ecteinascidia turbinate. This drug has a new mechanism of action based on DNA minor-groove binding.
View Article and Find Full Text PDFArticle Synopsis
- Effective treatment options for advanced cervical cancer are limited, with cisplatin-based chemotherapy showing low success rates and poor survival outcomes.
- Increased interest in targeted therapies has emerged due to a deeper understanding of tumor cell molecular changes, leading to new treatment possibilities.
- Promising targets for therapy include EGFR and VEGF, with monoclonal antibodies and receptor tyrosine kinase inhibitors under clinical evaluation for their effectiveness in treating cervical cancer.